Breast cancer is one of four oncology diseases that are most widespread in the world. Moreover, breast cancer is one of leading causes of cancer-related deaths in female population within economically developed regions of the world. So far, detection of new mechanisms of breast cancer development is very important for discovery of novel areas in which therapy approaches may be elaborated. The objective of the present study is to investigate involvement of proteasomes, which cleave up to 90% of cellular proteins and regulate numerous cellular processes, in mechanisms of breast cancer development. Proteasome characteristics in 106 patient breast carcinomas and adjacent tissues, as well as relationships of detected proteasome parameters with clinical-pathological factors, were investigated. Proteasome chymotrypsin-like activity was evaluated by hydrolysis of fluorogenic peptide Suc-LLVY-AMC. The expression of proteasome subunits was studied by Western-blotting and immunohistochemistry. The wide range of chymotrypsin-like activity in tumors was detected. Activity in tumors was higher if compared to adjacent tissues in 76 from 106 patients. Multiple analysis of generalized linear models discovered that in estrogen a-receptor absence, tumor growth was connected with the enhanced expression of proteasome immune subunit LMP2 and proteasome activator PA700 in tumor (at 95% confidence interval). Besides, by this analysis we detected some phenomena in adjacent tissue, which are important for tumor growth and progression of lymph node metastasis in estrogen a-receptor absence. These phenomena are related to the enhanced expression of activator PA700 and immune subunit LMP7. Thus, breast cancer development is connected with functioning of immune proteasome forms and activator PA700 in patients without estrogen a-receptors in tumor cells. These results could indicate a field for search of new therapy approaches for this category of patients, which has the worst prognosis of health recovery.
Introduction
Proteasomes, ''ubiquitous'' protease systems, regulate numerous cellular processes by protein degradation and/or peptide production in all organs and tissues including malignant tumors [1] [2] [3] [4] [5] . Among proteasome forms, the special role in tumor fate belongs to immune proteasomes. Immune proteasomes contain immune protease subunits LMP7(b5i), LMP2(b1i), and LMP10(MECL1, b2i) instead of constitutive protease subunits X(b5), Y(b1), and Z (b2) of constitutive proteasomes. Subunits X and LMP7 possess chymotrypsin-like (ChTL) activity, subunits Y and LMP2 possess caspase-like activity, and subunits Z and MECL1-trypsin-like activity [6] . However, substrate binding pockets of immune proteasomes differ from those of constitutive ones [7] . So, immune proteasomes display the altered cleavage site preference with a strong predominance to cleave behind basic or hydrophobic residues that represent the correct C terminus of a major histocompatibility complex (MHC) class I epitope. Antigenic epitopes produced from tumor proteins are transported with MHC class I molecules on the tumor cell surface for their further presentation to cytotoxic T-CD8 + lymphocytes. Thus, immune proteasomes display anticancer function by forming antigenic epitopes in tumor cells. However, immune proteasomes may play another role and favor cell survival by quenching the oxidative stress [8, 9] .
Our previous studies revealed different patterns of immune proteasome expression in rodent tumors. In ascitic carcinoma Krebs-II having developed in mice, the level of immune subunits LMP7 and LMP2 was very low in comparison with normal tissues [10] . In carcinosarcoma Walker 256 developing in WAG rats, only the level of immune subunit LMP2 was very low [11] . These facts are connected with mechanisms allowing tumor cells to avoid immune system surveillance. On the contrary, in cells of mouse hepatocellular carcinoma, the level of immune subunits LMP7 and LMP2 considerably increased in comparison with normal cells. Perhaps, immune proteasomes assist this type of tumor cells to overpass stress conditions [12] . In this case, escape of tumor cells from immune system is connected with other mechanisms not related to immune proteasomes. Thus, each tumor type has its own pattern of immune proteasome expression depending on the functions immune proteasomes perform.
Some special proteasome functions depend on proteasome regulators, in particular, on activator PA700 (19S). This activator is responsible for binding to ubiquitinated target proteins, unfolding and directing them into the proteasome proteolytic chamber [1, 2] . Previously we discovered that PA700 expression increased in growing malignant tumors, namely, in ascitic carcinoma Krebs-II and hepatocellular carcinoma in mice [10, 12] . At the same time, PA700 expression dramatically decreased in regressing carcinosarcoma Walker 256 in Brattleboro rats with the hereditary defect of arginine-vasopressin synthesis [11] . These results show that PA700 activator is very important for protein metabolism in actively proliferating tumor cells, and its lack is related with tumor regression and disappearance.
Thus, immune proteasomes and activator PA700 are key components of rodent proteasome pool that influence tumor fate. Changes of the amount of immune subunits and activator PA700 lead to the changes of proteasome activities. On the whole, the state of the proteasome system may be a unique characteristic of the certain stage of tumor development. Thus, the apprehension of peculiarities of proteasome functioning in malignant tumors of patients may clear up the mechanisms of tumor growth and metastasis, and may be important for the development of novel approaches to anticancer therapy.
According to the data of International Agency for Research on Cancer, one of four oncology diseases that are most widespread in the world is breast cancer. Moreover, breast cancer is the one of leading causes of cancer-related deaths in female population within economically developed regions of the world [13] . So far, this disease needs detailed investigation. To investigate mechanisms of breast cancer development, it is necessary to take into consideration not only its diversity by histological tumor types and stages, but also its heterogeneity by the expression of sex steroid hormone receptors and other patient clinical-pathological features, which may influence tumor development. The additional intrigue lies in the fact that proteasomes control the functioning of estrogen a receptors (ERa). These receptors undergo ubiquitination and consequent proteasomal degradation in ligand-independent or ligand-dependent manner. Degradation of unliganded ERa is involved in the quality control of the receptor. Cyclical recruitment of E3 ligases that accomplish ubiquitination, to liganded ERa and binding of ERa to the proteasome, are necessary for transcriptional activation of estrogen-responsive promoters [14] [15] [16] [17] . This fact enhances the importance of studying the relation between proteasome functioning and hormone receptor expression. The scarce published data on proteasomes in human breast cancer are mainly concerned with the comparison of the content of separate proteasome subunits and ChTL activity in tumor and control tissues [18] [19] [20] [21] [22] [23] . The main goal of the present study was to evaluate the hypothesis whether immune proteasomes and activator PA700, which have influence on the fate of animal tumors, are connected with the development of human breast cancer. We were also interested in clarification of the question about possible relationship of total proteasome pool expression and activity with the development of human breast cancer. To answer these queries, we took into account patient clinicalpathological factors, such as expression of progesterone receptors (PR) and ERa in cancer tissue, disease stage, lymph node metastasis, histological tumor type, presence or absence of menstrual cycle, applied neoadjuvant chemotherapy, age. We discovered that disease stage was connected with the expression of activator PA700 and some forms of immune proteasomes in tumor and adjacent tissues in patients without ERa in tumor cells. 
Materials and Methods

Ethics Statement
Antibodies and reagents
Combined mouse monoclonal antibodies (mAbs) to subunits a1,2,3,5,6,7, mouse mAbs to subunit Rpt6, to immune subunit LMP2 and to immune subunit LMP7, rabbit polyclonal antibodies (pAbs) to immune subunit LMP2 and to immune subunit LMP7 were purchased from Enzo Life Sciences (UK). Mouse mAbs to bactin, peroxidase-conjugated goat anti-mouse IgG antibodies and peroxidase-conjugated goat anti-rabbit IgG antibodies were purchased from Santa Cruz (Germany). Mouse mAbs to cytokeratin 18 were purchased from Chemicon (USA). ECL reagents were purchased from GE Healthcare (UK). Proteasome substrate N-succinyl-leu-leu-val-tyr7-amido-4-methyl coumarin (Suc-LLVY-AMC) and proteasome inhibitor Z-leucyl-leucylleucinal (MG132) were purchased from Sigma (USA). Peroxidase blocking reagent, LSAB2 System-HRP, mouse mAbs to ERa (clone 1D5), mouse mAbs to PR (clone PgR 636) and biotinilated anti-mouse IgG antibodies were purchased from Dako (Denmark). Hoechst 33342, Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 594 donkey anti-mouse IgG were purchased from Invitrogen (USA).
Immunohistochemistry
Immunohistochemical analysis of ERa and PR expression was carried out by streptavidin-biotin method. Paraffin-embedded slices (4 mm) of primary tumors underwent dewaxing in 96% ethanol and cleansed by distilled water. Subsequently, the slices were immersed in citrate buffer (0.01 M, pH 6.0). High temperature antigen demasking was carried out in two stages: at first high-temperature microwave heating for 7 min at power 60 Watt, and 1 min cooling at room temperature, then heating for 7 min at power 40 Watt, and cooling for 20 min at room temperature. Endogenous peroxidase activity was blocked by incubating the slices in Peroxidase Blocking Reagent for 10 minutes. The slices were incubated for 1 hour at 25uC with mouse mAb to ERa or PR (1:50). Then biotinilated anti-mouse IgG antibodies (1:400) were placed to the slices for 10 min. The slices were washed thoroughly with PBS after each stage of the procedure. Then streptavidin-biotin complex was applied for 10 min. The antibody reaction was visualized by using a 3,39-diaminobenzidine as a chromogen and LSAB2 System-HRP. The slices were counterstained with hematoxylin, and mounted in balsam. Microscope Carl Zeiss Axiostar plus 1169-151 (Germany) was used for image analysis. The immunoreactivity of tumor cells was evaluated from 0 to 3 according to the extent of positive staining. The intensity is in the range from 0 to 3, with 0 being no staining, 1-weak staining, 2 -intermediate staining, and 3 -intense staining. A total score (TS) of hormone receptor was defined by: TS = 36A+26B+16C, where A is a per cent value of intense stained cells, B is a per cent value of intermediate stained cells, and C is a per cent value of weak stained cells. TS was ranged from 0 to 300.
For evaluation of the proteasome subunit distribution in cells, samples of tumors were fixed in 4% paraformaldehyde and frozen. Cryostat sections (10 mm) were subsequently incubated at room temperature with: 1) PBS containing 1% of BSA and 0.1% Triton 
Preparation of cleared homogenates
All procedures were performed at 4uC. Frozen samples of tumor and adjacent tissues were homogenized in a dispergator ''IKA ultra turrax'' (Germany) in buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol, 10 mM Na 2 S 2 O 5 in the ratio 1:6 (w:v). Homogenates were centrifuged at 10,000 g for 30 min. Supernatants (cleared homogenates) were used for further investigation. Protein concentration in cleared homogenates was determined by Lowry method [24] .
Determination of the proteasome ChTL activity
Proteasome ChTL activity was determined by hydrolysis of fluorogenic peptide Suc-LLVY-AMC. The reaction mixture contained 20 mM Tris-HCl (pH 7.5), 1 mM dithiothreitol, 5 mM MgCl 2 , 1 mM ATP, and 30 mM Suc-LLVY-AMC. The reaction was performed at 37uC for 20 min after the introduction of 125 ml of the proteasome fraction (cleared homogenate) into the reaction mixture (to the final volume of 100 ml) and stopped by the addition of 1% SDS. The resulting product was detected by a fluorimeter (Hitachi, Japan) with the excitation wavelength of 380 nm and the emission wavelength of 440 nm [25] . To calculate the contribution of extrinsic proteolytic activities, MG132 as the inhibitor of ChTL proteasome activity was used. The effect of this inhibitor was preliminarily investigated with the use of proteasomes purified from the rat liver and liberated from admixed proteases as described earlier [26] . 5 mM MG132 completely inhibited ChTL activity of purified proteasomes. So, the final calculation of ChTL proteasome activity was performed as the difference between the total and residual activities in the presence of 5 mM MG132. ChTL activity was expressed as quantity of substrate (in units of fluorimeter indication) hydrolyzed at 37uC for 20 min and normalized to 1 mg of protein.
Western blot analysis
After SDS-PAGE in 13% gel (10 ml of cleared homogenate/ 100-130 mg of protein per lane), polypeptides were transferred from the gel onto PVDF membrane (Immobylon, Millipore, USA). Immunodetection was carried out in accordance with procedure for ''SNAP i.d.'' (Millipore, USA) with the use of primary antibodies to subunits LMP7, LMP2, Rpt6, a1,2,3,5,6,7 (1:1500) and b-actin (1:500).
The image analysis was performed using standard ImageJ software. The relative quantities (pixel intensity) of the immunoreactive bands on X-ray film were measured. The dependence of the pixel intensity on the amount of the protein subjected to Western blotting was evaluated preliminarily. For the further procedure, the diapason of the protein amount was chosen, in which this dependence was linear.
To compare the pixel intensity of distinct proteasome subunit in multiple samples with each other, we used some recurring samples in different gels in SDS-PAGE. Results were normalized to 1 mg of protein for comparison with ChTL proteasome activity.
Statistical analysis
Data on each breast cancer patient were entered into appropriate database file and transferred for the analysis. The statistical analysis program Statistica 8.0 (Statsoft, 2008) was used in the research. Initially, patient clinical-pathological characteristics: age (,45/.45 yr); menstrual cycle (+/2); histological tumor type; disease stage (T 1-4 ); lymph node metastases (N 0-3 ); chemotherapy (2/+), the expression of ERa and PR (2/+) were assigned in the values 1, 2, 3, …, n. The proteasome ChTL activity and quantities of proteasome and activator subunits in tumor and adjacent tissues from each patient were clustered into subgroups, according to values. Subgroups were ranked in the values 1, 2, 3, …, n. Spearman ranked order correlation analysis of all variables was performed. After that, the regression analysis based on nonlinear models was conducted. To assess regression data, we applied likelihood statistics and Wald statistics (W) (because it gives more reliable results). Simple regression analysis of generalized linear models (GLM) was also applied. To reveal the simultaneous effect of different factors on proteasome characteristics, multiple GLM analysis was performed. The multivariate research was used to examine the associations between indicated proteasome characteristics and patient clinical-pathological parameters. All predictor variables were treated as ordinal/continuous and categorical variables. Factors significant at p,0.05 were entered into the multivariate models. Models were examined using both no-selection and stepwise selection techniques.
Results
Histology of tumors and expression of sex steroid hormone receptors
Histological analysis of breast tumors revealed 88 samples of invasive ductal carcinoma (IDC), 11 samples of invasive lobular carcinoma (ILC). Besides, rare types of breast cancer, such as medullary cancer (MdC) and mucinous cancer (McC), were discovered. MdC and McC were combined in the distinct group named ''other types'' (7 samples).
In this study, we focused our attention on the research of a type of ER, since this type of receptors is involved in the process of cellular proliferation [27] . Breast tumors under investigation were characterized by a wide range of ERa and PR levels (TS from 0 to 285).
Distribution of proteasome subunits in tumor tissue cells
The distribution of the total proteasome pool was investigated according to the expression of a1,2,3,5,6,7 subunits included in all proteasome forms. The distribution of immune proteasomes containing LMP2 and/or LMP7 subunits was analyzed on the basis of the expression of these subunits. The third immune subunit MECL1 is known to be integrated into assembling proteasomes jointly with subunit LMP2 but independently from subunit LMP7 [28, 29] . So, we focused our attention on the expression of subunits LMP2 and LMP7. The distribution of proteasome activator PA700 was studied on the basis of the expression of subunit Rpt6 included in the structure of this activator. Figs. 1, 2, and 3 reflect the distribution of proteasomes and activator PA700 in IDC samples. The method of double immunofluorescent labeling discovered that cytoplasm of tumor cells contained immune proteasomes among total proteasome pool ( Figs. 2A and 3A) . Also, immune proteasomes were colocalized with activator PA700 in cytoplasm of tumor cells (Figs. 2B and  3B ). At the same time, a1,2,3,5,6,7 subunits as well as PA700 activator were detected in nuclei of tumor cells (Figs. 2 and 3) . This reflects the expression of proteasomes containing constitutive protease subunits in nuclei.
Note that we identified IDC cells as cellular congestions localized in ducts and fibrous stroma according to morphological characteristics detected by histological analysis. These congestions were clearly revealed by Hoechst 33342 labeling of cellular nuclei (Fig. 1) . Breast tumor cells are known to express cytokeratin 18 at the high level [30] . So, we applied the additional approach to identification of tumor cells by labeling them with the use of mAb to cytokeratin 18. 
Proteasome characteristics and their connection with clinical-pathological factors
We explored ChTL activity of the total proteasome pool in all tumor and adjacent tissues. Besides, we studied the expression of subunits a1,2,3,5,6,7, LMP2, LMP7 and Rpt6 in these tissues by Western blotting and analyzed the connection of these parameters with clinical-pathological factors. Note that high levels of proteasome subunit mRNA do not always correlate with high protein levels, suggesting a specific translation mechanism which controls proteasome subunit synthesis [31] . So, our attention was paid exactly to the protein expression of proteasome subunits. The wide range of proteasome ChTL activity (4-207 conditional units/mg of protein) in tumor was detected. ChTL activity in adjacent tissues lied in the range of 3-91 conditional units/mg of protein. Magnitudes of ChTL activity in the range of 113-207 conditional units/mg of protein in tumor were 2-11 times higher than in adjacent tissue. On the whole, ChTL activity was higher in tumor if compare to adjacent tissue in 76 from 106 patients. Nonparametric analysis of rank values discovered that ChTL activity in adjacent tissue was correlated with ChTL activity in tumor (r = 38%; p,0.05) and neoadjuvant therapy (r = 22%; p, 0.05). Simple GLM regression analysis revealed that difference of ChTL activity in tumor and adjacent tissue depended on ChTL activity in tumor, but not in adjacent tissue (Fig. 5) . For further investigation, we used maximum likelihood statistics and Wald statistics. It is shown that ChTL activity in tumor depends on index ranks of LMP7 amount in tumor (W = 3.8; p = 0.04). Index ranks are (1) Because of the heterogeneity of tumor samples by histological types and expression of sex steroid hormone receptors, it was important to evaluate the simultaneous effects of each of these factors with other clinical-pathological parameters on proteasome characteristics. The investigation was performed by multiple GLM analysis, which can reveal relationships undetectable by other statistical methods. We checked the simultaneous effect of the disease stage and factor of ERa absence or ERa presence on the quantity of subunits LMP2, LMP7, Rpt6 in primary tumor and adjacent tissue. The dependence of the quantity of LMP2 subunit in tumor, LMP7 subunit in adjacent tissue and Rpt6 subunit both in tumor and adjacent tissue on the simultaneous effect of the disease stage and factor of ERa absence or ERa presence, was revealed (Figs. 6 and 7) . The statistical indicators are shown in Table 1 . In ERa absence, these proteasome parameters considerably increased with tumor stage. Namely, the quantity of LMP2 subunit in tumor was higher at the stage T 4 than at the stages T 1 and T 2 . At the stage T 3 , it had middle value between the stages T 2 and T 4 but did not differ statistically. The quantities of subunits LMP7 in tumor, Rpt6 in tumor and Rpt6 in adjacent tissue were reliably higher at the stage T 4 than at the stages T 1 , T 2 and T 3 . On the contrary, in ERa presence all these proteasome parameters did not differ with tumor stage. We discovered similar dependence of the amount of LMP7 subunit (F = 3.15; p = 0.037) and Rpt6 subunit (F = 2.80; p = 0.05) in adjacent tissue on lymph node metastasis progression from N 2 to N 3 , in ERa absence (data not shown). In ERa presence, these proteasome parameters did not change. Note that LMP7 subunit amount in tumor did not change reliably with tumor stage either in ERa presence or in ERa absence (Figs. 6-7) . Effect of PR expression on proteasome characteristics was not revealed by any statistical method.
Also, we investigated the simultaneous effect of lymph node metastasis and histological tumor type on the amount of subunits LMP2, LMP7, Rpt6 in primary tumor and adjacent tissue. The dependence of the quantity of LMP7 and Rpt6 subunits in tumor and adjacent tissue on the simultaneous effect of examined factors was revealed (Fig. 8) . The statistical indicators are shown in Table 1 . For ILC samples, the amount of LMP7 subunit in tumor decreased with metastasis progress from N 0 to N 1 . For samples of ''other types'' (MdC+McC), the amount of LMP7 subunit in adjacent tissue and Rpt6 subunit both in tumor and adjacent tissue, increased with metastasis progress from N 0 to N 3 .
Discussion
The present study discovered peculiarities of proteasome functioning in breast cancer. In spite of high variability of patient clinical-pathological parameters, some important relationships were revealed. Namely, in ERa absence, the development of breast carcinoma is connected with the enhanced expression of proteasome subunit LMP2 and activator PA700 in tumor tissue. It was in tumor cells (not stroma cells) that the main amounts of subunit LMP2 and activator PA700 were fixed by method of immunohistochemistry. Relationships like these were earlier detected for thyroid cancer [32] . Perhaps, immune subunit LMP2 performs anti-stress functions in cells of these tumors and promotes their survival. The high expression of activator PA700 in dividing tumor cells is important for strict control of cell cycle and other cellular processes [33] .
Besides, we detected some phenomena in adjacent tissue, which are important for tumor growth and lymph node metastasis progression in the absence of ERa in tumor. These phenomena are related to the greatly enhanced expression of activator PA700 and immune proteasomes containing LMP7 subunit. Such phenomena in adjacent tissue were also revealed in lymph node metastasis progression in the group of McC+MdC irrespectively of ERa expression. Activator PA700 and LMP7 subunit probably are involved in degradation processes to facilitate cancer expansion. This fact requires further investigation. However, at the present time, we can speculate about two probable explanations. Firstly, in cells surrounding the growing tumor, protein metabolism with proteasome participation may be reorganized and directed to maintenance of tumor growth. This consideration is founded by a known feature of breast cancer cells to subjugate fibroblasts [34] . Secondly, surrounding cells are likely to supply proteasomes to extracellular environment by exocytosis to hydrolyze matrix or other substrates and provide tumor invasion as matrix metalloproteinases do [35] . This viewpoint is based on the fact of existence of extracellular proteasome pool [36] .
As the whole, the results indicate immune subunits and PA700 activator as components essential for breast cancer development. Besides, taking into account our previous data showing the connection of tumor regression in Brattleboro rats with sharply decreased PA700 level [11] , we could note the significance of consideration of PA700 activator as a possible target for new drug development.
The discovered complicated dependence of subunit LMP2 expression in tumor on the simultaneous effect of ERa expression and disease stage raises the question, how ERa may influence LMP2 expression in such intricate manner? It may be explained by the functioning of ERa as a factor which regulates LMP2 expression indirectly, through pathway with participation of microRNA (MIR) and some transcription factors. It is known for breast cancer that ERa induces MIR-191 expression [37] . In its turn, MIR-191 downregulates large set of genes including SOX4 in breast cancer [38] . Transcription factor SOX4 reduces mRNA levels of transcription factor PU.1 (SPI 1) in human acute myeloid leukemias [39] . This may be also the case for breast cancer, as PU.1 (SPI 1) is discovered in breast cancer too (Dataset NCBI GEO Profiles, ID: 2383767, 6783968, 77599439, 77894723, 82510260). PU.1 (SPI 1) directly binds and transactivates the promoter of PSMB9 (LMP2) [40] . Besides, MIR-145 and MIR-125b may participate in network and influence ERa expression directly [41, 42] or through transcription factor MYC [43] [44] [45] . Possible regulatory network between ERa and subunit LMP2 is shown in Fig. 9 . Taking into consideration the fact that proteasomes control transcriptional function of ERa, we can speculate about the existence of feedback between the proteasome system and ERa in breast cancer which is regulated in the complicated network.
One of significant results is the detection of the wide range of proteasome ChTL activity in tumor samples. Tumors with magnitudes of ChTL activity in the range of 113-207 conditional units/mg of protein are likely to be most dependent on this proteasome parameter. Therefore, they may be most sensitive to inhibitors of ChTL activity. At the same time, there were plenty of patients with low ChTL activity in tumor cells at each stage of the disease. Perhaps, the influence of proteasome inhibitors on tumor cells with low ChTL activity may be commensurable with their effect on normal cells with basic low ChTL activity in different organs. Note that antitumor drug Velcade, inhibitor of proteasome ChTL activity, is applied in doses which minimize its overall-toxic action. For most solid tumor populations, including breast cancer, this drug has not shown sufficient effect [46] . Probably, one of the explanations of this fact is the presence of tumor cells with low proteasome ChTL activity.
As it was expected, ChTL activity in tumor was associated with the expression of proteasome subunit LMP7 exhibiting this activity. At the same time, the expression of LMP2 subunit was not related to ChTL activity in breast cancer, although some authors showed the connection between these parameters in mouse fibroblasts after their treatment by interferon c [47] .
Thus, the data obtained are significant for realizing the molecular mechanisms of breast cancer development. The most significant result is revealing the relation of breast cancer growth and lymph node metastasis progression with functioning of immune proteasome forms and activator PA700 in tumor and surrounding cells in patients without ERa in tumor cells. These data could indicate a field for search of new therapy approaches for this category of patients. It is important because at the present time these patients have the worst prognosis of health recovery because of futility of the therapy for them, which blocks ERasignaling.
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